Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy

G. L. Banna, R. Di Quattro, L. Malatino, G. Fornarini, A. Addeo, M. Maruzzo, V. Urzia, F. Rundo, H. Lipari, U. De Giorgi, U. Basso

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To identify patients with metastatic urothelial cancer (mUC) unlikely to benefit from immune-checkpoint inhibitors (ICIs). Methods/Patients: We explored the predictive and prognostic values of baseline neutrophil-to-lymphocyte ratio (NLR), with cut-offs ≥ 3 and ≥ 5, and of a urothelial immune prognostic index (UIPI, based on increased NLR and LDH), on 146 patients. Results: NLR and UIPI significantly predicted progressive disease and progression-free survival with both cut-offs (p = 0.0069, p = 0.0034, p = 0.0160, p = 0.0063; p < 0.001, p = 0.021, p = 0.014, p = 0.026; for NLR-3, NLR-5, UIPI-3, UIPI-5, respectively) and overall survival when NLR cut-off was ≥ 5 (p = 0.03 and p = 0.024, for NLR-5 and UIPI-5, respectively). Conclusions: NLR-5 deserves prospective validation to identify mUC patients with poor prognosis following ICIs.

Original languageEnglish
JournalClinical and Translational Oncology
DOIs
Publication statusAccepted/In press - Jan 1 2020

Keywords

  • Biomarker
  • Immunotherapy
  • LDH
  • Neutrophil-to-lymphocyte ratio
  • Prognostic
  • Urothelial cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy'. Together they form a unique fingerprint.

Cite this